JP2018517734A - デフェラシロクスの改善された製剤およびその作製方法 - Google Patents

デフェラシロクスの改善された製剤およびその作製方法 Download PDF

Info

Publication number
JP2018517734A
JP2018517734A JP2017565048A JP2017565048A JP2018517734A JP 2018517734 A JP2018517734 A JP 2018517734A JP 2017565048 A JP2017565048 A JP 2017565048A JP 2017565048 A JP2017565048 A JP 2017565048A JP 2018517734 A JP2018517734 A JP 2018517734A
Authority
JP
Japan
Prior art keywords
dfx
poly
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017565048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517734A5 (enExample
Inventor
デーブ エイ． ミラー
デーブ エイ． ミラー
ジャスティン エム． キーン
ジャスティン エム． キーン
サンドラ ユー． クセラ
サンドラ ユー． クセラ
Original Assignee
ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー
ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー, ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー filed Critical ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー
Publication of JP2018517734A publication Critical patent/JP2018517734A/ja
Publication of JP2018517734A5 publication Critical patent/JP2018517734A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017565048A 2015-06-17 2016-06-17 デフェラシロクスの改善された製剤およびその作製方法 Pending JP2018517734A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180998P 2015-06-17 2015-06-17
US62/180,998 2015-06-17
PCT/US2016/038089 WO2016205658A1 (en) 2015-06-17 2016-06-17 Improved formulations of deferasirox and methods of making the same

Publications (2)

Publication Number Publication Date
JP2018517734A true JP2018517734A (ja) 2018-07-05
JP2018517734A5 JP2018517734A5 (enExample) 2019-05-30

Family

ID=57546755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017565048A Pending JP2018517734A (ja) 2015-06-17 2016-06-17 デフェラシロクスの改善された製剤およびその作製方法

Country Status (10)

Country Link
US (4) US10265301B2 (enExample)
EP (1) EP3310354B1 (enExample)
JP (1) JP2018517734A (enExample)
CN (1) CN107847490A (enExample)
AU (3) AU2016280280B2 (enExample)
CA (1) CA2989145C (enExample)
HK (1) HK1254608A1 (enExample)
IL (1) IL256322B (enExample)
MA (1) MA43271A (enExample)
WO (1) WO2016205658A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2565279T3 (en) 2007-12-05 2015-02-16 Complete Genomics Inc Efficient base determination in sequencing reactions
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
CN102459592B (zh) 2009-06-15 2017-04-05 考利达基因组股份有限公司 用于长片段阅读测序的方法和组合物
US10837879B2 (en) 2011-11-02 2020-11-17 Complete Genomics, Inc. Treatment for stabilizing nucleic acid arrays
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
EP3852711A4 (en) * 2018-09-20 2022-06-08 Tautona Group IP Holding Company, L.L.C. IRON-CHELATING COMPOUNDS FOR THE TREATMENT OF AESTHETIC SKIN DISORDERS
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
IL297776A (en) 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
CN112870361A (zh) * 2021-01-28 2021-06-01 重庆医科大学 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用
CN114994205B (zh) * 2022-05-30 2023-03-28 上海奥科达医药科技股份有限公司 地拉罗司颗粒剂中相关杂质的检测方法
WO2025151876A1 (en) * 2024-01-11 2025-07-17 Minneamrita Therapeutics Llc Triptolide formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512893A (ja) * 2009-12-07 2013-04-18 マピ ファーマ リミテッド デフェラシロクスの調製方法、及びデフェラシロクスの多形体
WO2014181108A1 (en) * 2013-05-10 2014-11-13 Cipla Limited Low dose pharmaceutical composition
JP2014221816A (ja) * 2007-08-21 2014-11-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医薬品適用のための熱−動力学的混合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
RU2008119410A (ru) * 2005-10-19 2009-11-27 Новартис АГ (CH) Диспергируемые таблетки, включающие деферасирокс
EP2062572A1 (en) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
EP2291360A2 (en) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Solid state forms of deferasirox salts and process for the preparation thereof
KR20130041144A (ko) * 2010-07-08 2013-04-24 라티오팜 게엠베하 데페라시록스의 경구투여용 제제
WO2012025935A2 (en) * 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
PE20170468A1 (es) * 2010-10-01 2017-04-26 Cipla Ltd Composicion farmaceutica que comprende deferasirox
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
SG11201506491RA (en) * 2013-03-08 2015-09-29 Novartis Ag Oral formulations of deferasirox

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014221816A (ja) * 2007-08-21 2014-11-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医薬品適用のための熱−動力学的混合
JP2013512893A (ja) * 2009-12-07 2013-04-18 マピ ファーマ リミテッド デフェラシロクスの調製方法、及びデフェラシロクスの多形体
WO2014181108A1 (en) * 2013-05-10 2014-11-13 Cipla Limited Low dose pharmaceutical composition
JP2016518398A (ja) * 2013-05-10 2016-06-23 シプラ・リミテッド 低用量医薬組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AAPS PHARMSCITECH, 2010, VOL.11, NO.2, PP760-774, JPN6020007104, ISSN: 0004425114 *
DRUG DISCOV. TODAY TECHNOL., 2012. VOL.9. NO.2, PP.E79-E85, JPN6020007097, ISSN: 0004425111 *
INT. J. PHARM., 2007, VOL.328, NO.2, PP.119-129, JPN6020007105, ISSN: 0004425115 *
INT. J. PHARM., 2011, VOL.419, NO.1-2, PP.222-230, JPN6020007101, ISSN: 0004425113 *
INT. J. PHARM., 2012, VOL.438, NO.1-2, PP.11-19, JPN6020007099, ISSN: 0004425112 *
INT. J. PHARM., 2013, VOL.450, NO.1-2, PP.185-196, JPN6020007095, ISSN: 0004425110 *

Also Published As

Publication number Publication date
AU2016280280B2 (en) 2021-09-02
IL256322B (en) 2022-03-01
US11878005B2 (en) 2024-01-23
US20170296514A1 (en) 2017-10-19
CN107847490A (zh) 2018-03-27
AU2021277731B2 (en) 2024-04-11
US10265301B2 (en) 2019-04-23
MA43271A (fr) 2018-09-26
HK1254608A1 (zh) 2019-07-26
AU2024202528A1 (en) 2024-05-09
IL256322A (en) 2018-02-28
US10258608B2 (en) 2019-04-16
CA2989145A1 (en) 2016-12-22
AU2021277731A1 (en) 2021-12-23
EP3310354A1 (en) 2018-04-25
EP3310354C0 (en) 2026-02-25
CA2989145C (en) 2024-10-29
EP3310354A4 (en) 2018-12-12
EP3310354B1 (en) 2026-02-25
US20170027911A1 (en) 2017-02-02
AU2016280280A1 (en) 2018-01-04
WO2016205658A1 (en) 2016-12-22
US20240091201A1 (en) 2024-03-21
AU2024202528B2 (en) 2026-01-08
US20190167643A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
AU2024202528B2 (en) Improved formulations of deferasirox and methods of making the same
JP7112333B2 (ja) 改善された薬物製剤
CN108601736A (zh) 前体脂质体十一酸睾酮制剂
US20250360085A1 (en) Improved drug formulations
WO2008104852A2 (en) Pharmaceutical compositions comprising adsorbate of fenofibrate
US20050038111A1 (en) Pharmaceutical formulation comprising bicalutamide
EP2953615A1 (en) Solid dispersion comprising amorphous cilostazol
WO2003043630A1 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor
CN107693516A (zh) 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
HK40000762A (en) Improved drug formulations
KR20120094556A (ko) 산성영역에서의 용출이 극대화된 부정맥치료제 제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210113

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210915